Skip to main content

Phibro Animal Health (PAHC) Receives a Hold from Morgan Stanley

Tipranks - Tipranks - Sat Feb 7, 8:50AM CST

Morgan Stanley analyst Erin Wright maintained a Hold rating on Phibro Animal Health today and set a price target of $49.00.

Claim 50% Off TipRanks Premium

Wright covers the Healthcare sector, focusing on stocks such as CVS Health, Cardinal Health, and Elevance Health. According to TipRanks, Wright has an average return of 14.7% and a 65.12% success rate on recommended stocks.

In addition to Morgan Stanley, Phibro Animal Health also received a Hold from TipRanks – xAI’s xAi Drug Manufacturers – Specialty and Generic in a report issued yesterday. However, on the same day, Bank of America Securities reiterated a Sell rating on Phibro Animal Health (NASDAQ: PAHC).

See today’s best-performing stocks on TipRanks >>

Based on Phibro Animal Health’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $363.89 million and a net profit of $26.53 million. In comparison, last year the company earned a revenue of $260.43 million and had a net profit of $6.98 million

Read More on PAHC:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).